Analysis of Human NKT cell auto-antigens

人类 NKT 细胞自身抗原的分析

基本信息

  • 批准号:
    8044075
  • 负责人:
  • 金额:
    $ 35.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-04-15 至 2014-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): NKT cells are a population of regulatory T cells that is known to be able to potently modulate immune responses. The antigens that control NKT cell activation are lipids and glycolipids presented by CD1d molecules. A remarkable characteristic of NKT cells is that many are autoreactive to self antigens. This allows them to become activated even when there is no foreign antigenic challenge, and may be critical for their endogenous immunoregulatory effects. The auto-antigens recognized by human NKT cells have not been identified, and little is known about how their presentation is regulated. Here we will: i) characterize the endogenous ligands presented by human CD1d molecules, and analyze which ones are antigenic for NKT cells; ii) follow up on our preliminary results, which indicate that an intercellular lipid messenger called lyso- phosphatidylcholine (LPC) that is produced under inflammatory conditions, is a self antigen that can be recognized by many human NKT cells; iii) investigate the cellular and molecular requirements for CD1d-mediated auto-antigen presentation to NKT cells. These studies will provide new information about the lipid characteristics that are important for binding to human CD1d molecules and for recognition by NKT cells, and will explore how NKT cell activation is linked to broader physiological processes of inflammation through recognition of bio-active lipid mediators as self antigens, and will provide critical insights into the mechanisms by which CD1d- mediated auto-antigen presentation is regulated by APCs. PUBLIC HEALTH RELEVANCE: NKT cells are autoreactive regulatory T cells that recognize lipids and glycolipids as antigens presented by CD1d molecules. The molecular identity of the auto-antigens recognized by human NKT cells remains unknown. In this grant we will: i) identify constitutively presented cellular ligands that are recognized by human NKT cells; ii) investigate lipid messengers as putative inducible auto-antigens that may directly link NKT cell activation to inflammatory responses; and iii) analyze cellular and molecular requirements for auto-antigen presentation by CD1d.
描述(由申请人提供):NKT细胞是一群调节性T细胞,已知其能够有效调节免疫应答。控制NKT细胞活化的抗原是由CD 1d分子呈递的脂质和糖脂。NKT细胞的一个显著特征是许多对自身抗原具有自身反应性。这使得它们即使在没有外来抗原挑战的情况下也会被激活,并且可能对其内源性免疫调节作用至关重要。被人类NKT细胞识别的自身抗原尚未被鉴定,并且关于它们的呈递是如何被调节的知之甚少。在这里,我们将:i)表征由人CD 1d分子呈递的内源性配体,并分析哪些配体对NKT细胞具有抗原性; ii)对我们的初步结果进行跟踪,该结果表明在炎症条件下产生的称为溶血磷脂酰胆碱(LPC)的细胞间脂质信使是可以被许多人NKT细胞识别的自身抗原; iii)研究CD 1d介导的自身抗原呈递给NKT细胞的细胞和分子要求。这些研究将提供有关脂质特征的新信息,这些脂质特征对于与人CD 1d分子结合和NKT细胞识别非常重要,并将探索NKT细胞活化如何通过识别生物活性脂质介质作为自身抗原与更广泛的炎症生理过程联系起来,并将提供关键的见解CD 1d介导的自身抗原呈递的APC调节的机制。公共卫生相关性:NKT细胞是自身反应性调节性T细胞,识别脂质和糖脂作为CD 1d分子呈递的抗原。人NKT细胞识别的自身抗原的分子身份仍然未知。在此补助金中,我们将:i)鉴定由人NKT细胞识别的组成型呈递的细胞配体; ii)研究脂质信使作为推定的可诱导自身抗原,其可将NKT细胞活化与炎症反应直接联系起来;和iii)分析CD 1d对自身抗原呈递的细胞和分子要求。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jenny E. Gumperz其他文献

Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibililty complex haplotype
不同人类组织相容性白细胞抗原类型个体中NKB1自然杀伤细胞I类受体表达的异质表型似乎受到遗传调节,但与主要组织相容性复合体单倍型无关
  • DOI:
  • 发表时间:
    1996
  • 期刊:
  • 影响因子:
    15.3
  • 作者:
    Jenny E. Gumperz;N. Valiante;Peter Parham;Lewis L. Lanier;D. Tyan
  • 通讯作者:
    D. Tyan

Jenny E. Gumperz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jenny E. Gumperz', 18)}}的其他基金

Development of iPSC-derived iNKT cells to promote hematopoietic engraftment
开发 iPSC 衍生的 iNKT 细胞以促进造血植入
  • 批准号:
    10525780
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Development of iPSC-derived iNKT cells to promote hematopoietic engraftment
开发 iPSC 衍生的 iNKT 细胞以促进造血植入
  • 批准号:
    10632065
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Mechanisms of iNKT cell anti-viral adjuvancy
iNKT细胞抗病毒佐剂机制
  • 批准号:
    10456109
  • 财政年份:
    2018
  • 资助金额:
    $ 35.91万
  • 项目类别:
Mechanisms of iNKT cell anti-viral adjuvancy
iNKT细胞抗病毒佐剂机制
  • 批准号:
    9757690
  • 财政年份:
    2018
  • 资助金额:
    $ 35.91万
  • 项目类别:
Mechanisms of iNKT cell anti-viral adjuvancy
iNKT细胞抗病毒佐剂机制
  • 批准号:
    10215435
  • 财政年份:
    2018
  • 资助金额:
    $ 35.91万
  • 项目类别:
Understanding the impact of human NKT cells on hematopoiesis
了解人类 NKT 细胞对造血的影响
  • 批准号:
    9096694
  • 财政年份:
    2015
  • 资助金额:
    $ 35.91万
  • 项目类别:
Analysis of human NKT cells in GVHD in vivo
人 NKT 细胞在体内 GVHD 中的分析
  • 批准号:
    8247271
  • 财政年份:
    2012
  • 资助金额:
    $ 35.91万
  • 项目类别:
Analysis of human NKT cells in GVHD in vivo
人 NKT 细胞在体内 GVHD 中的分析
  • 批准号:
    8416354
  • 财政年份:
    2012
  • 资助金额:
    $ 35.91万
  • 项目类别:
Analysis of Human NKT cell auto-antigens
人类 NKT 细胞自身抗原的分析
  • 批准号:
    8093782
  • 财政年份:
    2010
  • 资助金额:
    $ 35.91万
  • 项目类别:
Functional analysis of human NKT cells and myeloid DCs within murine SCID hosts
小鼠 SCID 宿主体内人类 NKT 细胞和髓样 DC 的功能分析
  • 批准号:
    7356104
  • 财政年份:
    2009
  • 资助金额:
    $ 35.91万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 35.91万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 35.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了